Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD).
Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.
The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.
Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 22 |
| CEO | David G. Elsley MBA |
Contact Details
Address: 602-2265 Upper Middle Road East Oakville, A6 L6H 0G5 Ontario, Canada | |
| Phone | 289-910-0850 |
| Website | cardiolrx.com |
Stock Details
| Ticker Symbol | CRDL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001702123 |
| CUSIP Number | 14161Y200 |
| ISIN Number | CA14161Y2006 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David G. Elsley MBA | President, Chief Executive Officer and Director |
| Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | Chief Financial Officer, Corporate Secretary and Director |
| Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research & Development |
| Trevor Burns | Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Apr 1, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 26, 2024 | 6-K | Report of foreign issuer |
| Feb 21, 2024 | 6-K | Report of foreign issuer |
| Feb 15, 2024 | 6-K | Report of foreign issuer |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 24, 2024 | 6-K | Report of foreign issuer |
| Jan 9, 2024 | 6-K | Report of foreign issuer |
| Dec 5, 2023 | 6-K | Report of foreign issuer |
| Nov 16, 2023 | 6-K | Report of foreign issuer |